Medical cannabis for chronic pain evidence is growing, but benefits are modest, risks vary and product standards still shape real-world treatment choices.
CBD novel food compliance remains a decisive test for UK and EU brands. Here is what the rules mean for dossiers, labels, claims and market access today.
How cannabis reimbursement works across Europe: eligibility, prescriptions, insurer decisions, paperwork and the policy gaps patients still face today.
Medical cannabis versus opioids: evidence on pain relief, safety, prescribing and policy as Europe reassesses chronic pain treatment choices in practice.
Medical cannabis for chronic pain evidence is growing, but benefits are modest, risks vary and product standards still shape real-world treatment choices.
CBD novel food compliance remains a decisive test for UK and EU brands. Here is what the rules mean for dossiers, labels, claims and market access today.
How cannabis reimbursement works across Europe: eligibility, prescriptions, insurer decisions, paperwork and the policy gaps patients still face today.
Medical cannabis versus opioids: evidence on pain relief, safety, prescribing and policy as Europe reassesses chronic pain treatment choices in practice.